Inhibikase Therapeutics (IKT) Cash from Investing Activities (2022 - 2026)

Inhibikase Therapeutics (IKT) has reported Cash from Investing Activities for 5 consecutive years, with -$80.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 482.27% year-over-year to -$80.5 million; the TTM figure through Mar 2026 stood at -$99.5 million (down 687.19% YoY), while the FY2025 annual figure was $2.1 million, up 105.55% from the prior year.
• Cash from Investing Activities fell to -$80.5 million in Q1 2026 per IKT's latest filing, from -$98847.0 in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $21.1 million in Q1 2025 and bottomed at -$80.5 million in Q1 2026.
• Historically, Cash from Investing Activities has averaged -$7.5 million across 5 years, with a median of -$70968.0 in 2022.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities jumped 6017.7% — and 2024, when it slumped 1732.19%.
• Inhibikase Therapeutics' Cash from Investing Activities stood at $5.0 million in 2022, then plunged by 142.63% to -$2.1 million in 2023, then plunged by 1732.19% to -$38.8 million in 2024, then surged by 99.74% to -$98847.0 in 2025, then slumped by 81323.4% to -$80.5 million in 2026.
• Business Quant data shows IKT's Cash from Investing Activities at -$80.5 million in Q1 2026, -$98847.0 in Q4 2025, and -$28.7 million in Q3 2025.